Evidence map›Paper›PMID 22228829›Full record

ArticleJournal of geriatric psychiatry and neurology2011

Sertraline for the treatment of depression in Alzheimer disease: genetic influences.

Matthew E Peters, Vijay Vaidya, Lea T Drye, Paul B Rosenberg, Barbara K Martin, Anton P Porsteinsson, Constantine E Frangakis, Jacobo Mintzer, Daniel Weintraub, Lon S Schneider and 7 more

Erratum issuedOpen access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of geriatric psychiatry and neurology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Depression in cognitive impairment.Current psychiatry reports · 2013
    Review
4 · The record

Corrections and comments

  • Erratum issued
    Dimitri, Avramopoulos [corrected to Avramopoulos, Dimitri]
5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Matthew E PetersThe Johns Hopkins University, Baltimore, MD 21224, USA.
Vijay Vaidya
Lea T Drye
Paul B Rosenberg
Barbara K Martin
Anton P Porsteinsson
Constantine E Frangakis
Jacobo Mintzer
Daniel Weintraub
Lon S Schneider
Peter V Rabins
Cynthia A Munro
Curtis L Meinert
Constantine G Lyketsos
Dimitri Avramopoulos
Avramopoulos Dimitri
DIADS-2 Research Group
Johns Hopkins University · USRalph H. Johnson VA Medical Center · USUniversity of Pennsylvania · USUniversity of Rochester · USUniversity of Southern California · US

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
TRIAL OF VALPROATE TO ATTENUATE THE PROGRESSION OF ADU01AG010483 · NIA · UNIVERSITY OF ROCHESTER · PI AISEN, PAUL S. · 1991 to 2012
$116.2M
PREVENTION OF ALZHEIMER DEMENTIA &COGNITIVE DECLINEU01AG015477 · NIA · UNIVERSITY OF WASHINGTON · PI BREITNER, JOHN C S · 2000 to 2010
$44.4M
Citalopram Treatment for Agitation in Alzheimer DementiaR01AG031348 · NIA · JOHNS HOPKINS UNIVERSITY · PI LYKETSOS, CONSTANTINE G · 2008 to 2012
$7.9M
Research Infrastructure for the Hopkins Population CenterR24HD042854 · NICHD · JOHNS HOPKINS UNIVERSITY · PI CHERLIN, ANDREW J · 2003 to 2017
$5.1M
Depression in Alzheimer's Disease Study 2 (DIADS-2)U01MH066136 · NIMH · JOHNS HOPKINS UNIVERSITY · PI LYKETSOS, CONSTANTINE G · 2003 to 2007
$2.2M
Depression in Alzheimer's Disease-IIU01MH068014 · NIMH · JOHNS HOPKINS UNIVERSITY · PI MEINERT, CURTIS L · 2003 to 2007
$1.6M
Depression in Alzheimer's Disease Study 2 (DIADS-2)U01MH066175 · NIMH · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SCHNEIDER, LON S · 2003 to 2007
$600k
PET imaging of activated microglia in Alzheimer's DiseaseK08AG029157 · NIA · JOHNS HOPKINS UNIVERSITY · PI ROSENBERG, PAUL B · 2008 to 2012
$539k
Depression in Alzheimer's Disease Study-2(DIADS-2)U01MH066174 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI WEINTRAUB, DANIEL · 2003 to 2007
$384k
Depressoin in Alzheimer's Disease Study-2 (DIADS-2)U01MH066176 · NIMH · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MINTZER, JACOBO E. · 2003 to 2007
$359k
Depression in Alzheimer's Disease Study 2 (DIADS-2)U01MH066177 · NIMH · UNIVERSITY OF ROCHESTER · PI PORSTEINSSON, ANTON P · 2003 to 2007
$317k
NIA NIH HHS K08 AG029157NIA NIH HHS R01 AG031348NIA NIH HHS R01AG031348NIA NIH HHS U01 AG010483NIA NIH HHS U01 AG015477NIA NIH HHS U01 AG024904NIA NIH HHS U01AG024904NIA NIH HHS U01AG10483NIA NIH HHS U01AG15477NICHD NIH HHS R24 HD042854NIMH NIH HHS 1U01MH066136NIMH NIH HHS 1U01MH066174NIMH NIH HHS 1U01MH066175NIMH NIH HHS 1U01MH066176NIMH NIH HHS 1U01MH066177NIMH NIH HHS 1U01MH068014NIMH NIH HHS U01 MH066136NIMH NIH HHS U01 MH066174NIMH NIH HHS U01 MH066175NIMH NIH HHS U01 MH066177NIMH NIH HHS U01MH066177NIMH NIH HHS U01 MH068014
6 · The paper itself

Abstract

objectiveTo assess the potential for genetic influences on sertraline treatment efficacy for depression of Alzheimer disease (dAD). Four functional genetic variants were studied: 2 serotonin receptors (HTR2A-T102C and HTR2C-Cys23Ser), the serotonin transporter (5HTT-LPR), and brain-derived neurotrophic factor (BDNF-Val66Met). Treatment response by genotype was measured by (1) the modified Alzheimer's Disease Cooperative Study Clinical Global Impression of Change, (2) the Cornell scale for Depression in Dementia, and (3) remission of depression.

methodsWe utilized data from the Depression in Alzheimer's Disease Study 2 (DIADS-2), a 24-week, randomized, multicenter trial showing no significant treatment effect of sertraline on dAD. Proportional odds logistic regression and mixed effects models were used to examine the above mentioned outcome measures.

resultsNo significant interactions were seen between any of the genetic polymorphisms and the selected outcomes above at 12 or 24 weeks. DISCUSSION: Treatment outcomes in the DIADS-2 trial were not significantly influenced by genetic variation at the loci that were assessed. Future studies should continue to examine the interaction of depression-related genetic variants with antidepressant treatment in Alzheimer disease patients with depression.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseDepressionFemaleGenotypeHumansMaleMiddle AgedMulticenter Studies as TopicPolymorphism, GeneticRandomized Controlled Trials as TopicSelective Serotonin Reuptake InhibitorsSertralineTreatment OutcomeSelective Serotonin Reuptake InhibitorsSertraline

Identifiers

PMID22228829
PMCPMC3535452
OpenAlexW2074477450

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.